In the Claims:

1. (Currently Amended) An <u>isolated</u> immunogenic polypeptide comprising a sequence selected from the group consisting of residues 26 to 186 of SEQ ID NO: <u>29</u> 23 to 45, and 55.



- 2. (Currently Amended) The <u>isolated</u> immunogenic polypeptide of claim 1 further comprising about the N-terminal two thirds of the sequences selected from SEQ ID NO: 29 23 to 45, and 55.
- 3. (Currently Amended) The <u>isolated</u> immunogenic polypeptide of claim 1 wherein said polypeptide <u>comprises</u> has an amino acid sequence selected from the group consisting of SEQ ID NO: <u>29</u> 23 to 45, and 55.

4 - 9 (Withdrawn)

10. (Original) A vaccine composition comprising an immunogenically effective amount of an immunogenic polypeptide of claims 1, 2, or 3, wherein said immunogenic polypeptide is in a pharmacologically acceptable carrier.

11 – 38 (Withdrawn)